- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02583659
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Establish a clinical database for the advanced gastric cancer patients treated with first-line combined chemotherapy in Tongji hospital.
1.1.Data including age, gender, smoking state, karnofsky performance score(KPS), disease history, clinical stage, primary tumor site, metastasis site, surgery, first-line chemotherapy, therapy after failure of first-line treatment, radiotherapy, toxicity, survival time, the time of free of progress, response were collected.
1.2.The peripheral blood samples were collected for further biomarker reserch.
- Kaplan-Meier and Cox model will be used to analyze the overall survival(OS) and progression-free survival(PFS) of advanced gastric cancer.
- Extract Deoxyribonucleic acid(DNA) from the the peripheral blood and research biomarkers related to the first-line combined chemotherapy for AGC.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Rekrutierung
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
Hauptermittler:
- Xianglin Yuan, MD,PHD
-
Kontakt:
- Xianglin Yuan, MD,PHD
- Telefonnummer: 1 13667241722
- E-Mail: yxl@medmail.com.cn
-
Kontakt:
- Suxian Wei, Master
- Telefonnummer: 1 15927421058
- E-Mail: wsxattj@126.com
-
Unterermittler:
- Suxian Wei, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma;
- Unresectable locally advanced, or recurrent, or metastasis disease;
- Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed.
- Life expectancy of at least 3 months;
- ECOG score 0-2;
- Voluntarily signed the informed consent.
Exclusion criteria:
- Previously treated with first-line chemotherapy;
- First-line chemotherapy with single drug.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Combined chemotherapy
AGC patients treated with first-line combined chemotherapy
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Overall survival(OS) . overall survival Overall survival(OS)
Zeitfenster: From date of enrollment until the date of death from any cause, assessed up to 60 months
|
From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Progression-free survival(PFS)
Zeitfenster: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
|
Objective response rate(ORR)
Zeitfenster: The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
|
Disease control rate(DCR)
Zeitfenster: The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Zeitfenster: Through first-line treatment completion,up to 24 weeks.
|
Through first-line treatment completion,up to 24 weeks.
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Xianglin Yuan, MD,PHD, Tongji Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TJCC004
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .